Amicus Therapeutics Announces Second Quarter 2017 Financial Results and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Amicus Therapeutics (FOLD) Reports Q2 Loss of $0.34
August 7, 2017 7:03 AM EDTAmicus Therapeutics (NASDAQ: FOLD) reported Q2 EPS of ($0.34), versus ($0.40) reported last year. Revenue for the quarter came in at $7.2 million, versus $4.2 million reported last year.
179 Fabry Disease Patients on Reimbursed Galafold (migalastat) as of July 31 On Target to Reach 300 Patients by Year-End 2017Migalastat NDA Submission Targeted for 4Q17Phase 3 EB Topline Data and Complete Phase 1/2 Pompe Data on Track for Late 3Q17John F. Crowley, Chairman and Chief Executive... More
